Purple Biotech Ltd
TASE:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Purple Biotech Ltd
Short-Term Investments
Purple Biotech Ltd
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Short-Term Investments
$857k
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Short-Term Investments
$13m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Short-Term Investments
$6.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Short-Term Investments
$48.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
64%
|
CAGR 10-Years
31%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Short-Term Investments
₪39k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-31%
|
|
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
See Also
What is Purple Biotech Ltd's Short-Term Investments?
Short-Term Investments
857k
USD
Based on the financial report for Dec 31, 2025, Purple Biotech Ltd's Short-Term Investments amounts to 857k USD.
What is Purple Biotech Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
-55%
Over the last year, the Short-Term Investments growth was -24%. The average annual Short-Term Investments growth rates for Purple Biotech Ltd have been -63% over the past three years , -55% over the past five years .
